razoxane has been researched along with 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Douglass, HO; Engstrom, PF; Kaufman, J; Klaassen, D; MacIntyre, JM; Von Hoff, D | 1 |
| Arsenau, JC; Blessing, J; Lewis, GC; Slavik, M | 1 |
1 trial(s) available for razoxane and 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
| Article | Year |
|---|---|
Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Humans; Lomustine; Mesylates; Piperazines; Random Allocation; Razoxane; Rectal Neoplasms | 1985 |
2 other study(ies) available for razoxane and 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Etoposide; Female; Humans; Maytansine; Neoplasm Recurrence, Local; Pelvic Neoplasms; Piperazines; Razoxane; Research Design; Triazines | 1982 |